-
Gaps in Evidence on Burden and HRQoL in Small-Cell Lung Cancer: Findings From a Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Performance of Large Language Model Clinical Data Extraction by Data Domain: A Rapid Systematic Review
Sep 9, 2025, 16:22 PM -
NICE and CDA Assessment of Artificial Intelligence-Enabled Health Technologies: Analysis and Insights
Sep 9, 2025, 16:22 PM -
Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-Negative Breast Cancer (TNBC): Systematic Literature Review (SLR)
Sep 9, 2025, 16:22 PM -
Direct Healthcare Costs (HCCs) Inequalities Associated With Myasthenia Gravis (MG) in Hungary: Claims Database Analysis
Sep 9, 2025, 16:22 PM -
Clinical and Economic Benefits of Extended-Release Metformin In Prediabetes Management
Sep 9, 2025, 16:22 PM -
An Evaluation of the Cost of Treatment for Low-Back Pain Among Patients Attending Public Healthcare Facilities in Nigeria
Sep 9, 2025, 16:22 PM -
Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom
Sep 9, 2025, 16:22 PM -
Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe
Sep 9, 2025, 16:22 PM -
Characterizing Comorbidities and Co-Occurring Conditions in Adults with Generalized Anxiety Disorder in the United States
Sep 9, 2025, 16:22 PM -
Economic Burden of Schizophrenia: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Semaglutide in Transition: A Nationwide Register-Based Study in Finland 2019-2024
Sep 9, 2025, 16:22 PM -
Accumulating Evidence: When Publication Bias Persists
Sep 9, 2025, 16:22 PM -
Feasibility of Building a Generic Partitioned Survival Model for Oncology: Essential Components and Technical Implementation
Sep 9, 2025, 16:22 PM -
Understanding the Impact of Cost-Effectiveness Evaluations on Drug Pricing in Japan: A Case Study of Oncology Therapies
Sep 9, 2025, 16:22 PM -
The VIS1ON Horizon Scanning Model: Predicting the Evolution of Direct NHS Expenditure for Type 1 Diabetes in Italy up to 2028
Sep 9, 2025, 16:22 PM -
Health State Utilities Associated With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Sep 9, 2025, 16:22 PM -
Patient Pathways to Accessing Unregistered Medicines in Low-Priority Launch Markets
Sep 9, 2025, 16:22 PM -
The Cost of Complacency: Projecting the Burden of HIV Care in Eight European Countries
Sep 9, 2025, 16:22 PM -
Matching Adjusted Indirect Comparison of Asciminib vs. Flumatinib as First-Line Treatment for Chronic Myeloid Leukemia in China
Sep 9, 2025, 16:22 PM
